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Weinvestigatedglucosetoleranceandleftventricularcontractileperformancein4frequentlyusedmousestrains(Swiss,C57BL/6J,
DBA2, and BalbC) at 24 weeks. Glucose tolerance was tested by measuring blood glucose levels in time after intraperitoneal
glucose injection (2mg/g body weight). Left ventricular contractility was assessed by pressure-conductance analysis. Peak glucose
levels and glucose area under the curve were higher (all P<. 05) in C57BL/6J (418 ± 65mg/dL and 813 ± 100mg·h/dL)
versus Swiss (237 ± 66mg/dL and 470 ± 126mg·h/dL), DBA2 (113 ± 20mg/dL and 304 ± 49mg·h/dL, P<. 01), and BalbC
mice (174 ± 55mg/dL and 416 ± 70mg·h/dL). Cardiac output was higher (all P<. 05) in Swiss (14038 ± 4530μL/min) versus
C57BL/6J (10405 ± 2683μL/min), DBA2 (10438 ± 3251μL/min), and BalbC mice (8466 ± 3013μL/min). Load-independent left
ventricular contractility assessed as recruitable stroke work (PRSW) was comparable in all strains. In conclusion, glucose tolerance
and load-dependent left ventricular performance parameters were diﬀerent between 4 mice background strains, but PRSW was
comparable.
1.Introduction
Multiple transgenic mouse models have been and are being
developed in cardiovascular research to study hypertension
[1], diabetes [2], atherosclerosis [3], hypertrophic cardiomy-
opathy [4], heart failure [5], and many other diseases. These
diﬀerent experimental models are generated and studied in
diﬀerent mouse strains and genetic backgrounds.
Evaluating these disease models can be confounded not
only by diﬀerences in gender [6] or environment [7]b u t
also by baseline diﬀerences associated with their genetic
background [8]. Obtaining the baseline characteristics of
diﬀerent background strains may therefore lead to a better
understanding of cardiovascular research with laboratory
animals. Reference values concerning left ventricular con-
tractility parameters allow a more direct comparison and a
correct interpretation of obtained results in speciﬁc studies.
We hypothesize that four frequently used mice strains
(C57BL/6J, Swiss, BalbC, and DBA2 mice) exhibit a signif-
icantly diﬀerent baseline left ventricular contractility and
that glucose handling capacity is also diﬀerent between
these 4 strains. As glucose handling capacity could play
an important role in the development of diabetes mellitus
type 2 [9], hypertension [10], atherosclerosis [11], and
heart failure [12], our ﬁndings could contribute to a
better understanding of the decrease in left ventricular
contractility that accompanies these pathological conditions.
The C57BL/6J “black six” mouse is by far the most widely
used mouse inbred strain. The strain is characterised by a
high susceptibility to diet-induced obesity, with a moderate
hyperglycemia and hyperinsulinemia [13, 14]. Genetic dif-
ferences in metabolic response to fat have been suggested
to be more important in their development of obesity
and diabetes than calory intake [15]. Furthermore, they
appear highly susceptible to the development of atheroscle-
rosis on a semisynthetic high-fat diet [16], although their
p l a s m ac h o l e s t e r o ll e v e l sa t1 2a n d2 4w e e k sa r er a t h e rl o w
[17].
The Swiss mouse strain was originally selected in 1935 for
its ease in breading. It is an albino mouse strain, used over2 Journal of Biomedicine and Biotechnology
all the branches of biomedical research, especially in cancer
research [18], toxicity studies [19], and infective diseases
[20].
The BalbC strain is used as a general purpose strain
in many disciplines. They develop high plasma cholesterol
levels [21] and high systolic blood pressures [22]b u ta r e
resistant to diet-induced atherosclerosis [23]. Although their
mean heart rate is rather low, they show a high heart
rate adaptation [24]. BalbC mice show a high incidence
of epicardial mineralisation (11% in males and 4% in
females) which increases with age [25]. Overall heart defects,
including cardiac calcinosis, occur frequently in about 17–
62% [26].
Finally the DBA2 strain is a widely used strain in
cardiovascular, biological, and neurobiological research.
Their susceptibility for developing atherosclerotic lesions is
low and therefore are often contrasted with the C57BL/6
strain. The strain did not only show to be resistant to the
development of atherosclerosis on a semisynthetic high fat
diet [12] but also hyporesponsive to diets containing high
levels of cholesterol and fat [27]. Spontaneous calciﬁed heart
lesions progressively develop with age, and at 1 year 90% of
the mice are expected to be aﬀected [28]. Brunnert suggested
in 1997 [29] that dystrophic cardiac calciﬁcation may be
related to a disturbed myocyte calcium metabolism.
Although it is thus clear that these 4 strains have
diﬀerent metabolic characteristics, with inﬂuence on car-
diovascular disease development, no direct comparison of
glucose tolerance has been published in these strains, nor
wasleftventricularcontractilitysystematicallycompared.We
thereforeperformedinvivointraperitonealglucosetolerance
testing and cardiac pressure-conductance measurements in
Swiss, C57BL/6J, DBA2, and BalbC mice at 24 weeks.
2.MaterialsandMethods
2.1. Animals. 19 C57BL/6J, 14 BalbC, 14 DBA2, and 18
Swiss mice were investigated. All animals were purchased
form Jackson Laboratories (Bar Harbour, Maine, USA) and
housed at 22◦C on a ﬁxed 12-hour light-dark cycle. The
investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication no. 85-23, revised
1996).AllexperimentalprotocolswereapprovedbytheInsti-
tutionalAnimal CareCommission andEthicalCommittee of
the K.U.Leuven.
2.2.FastingIPGTTTesting. Intraperitonealglucosetolerance
testing was performed at 23 weeks with a bolus glucose
injection of 2mg/g body weight and followed by measuring
the blood glucose levels at ﬁxed timepoints (fasting and after
15, 30, 60, 120, and 240 minutes, resp.).
2.3. Left Ventricular Pressure-Conductance Measurements.
At 24 weeks, mice were anesthetized with a mixture
of urethane (1.2g/kg) and alpha-chloralose (50mg/kg)
injected intraperitoneally. Mice were placed on a heating
pad, and rectal temperature was kept between 36.0 and
37.5◦C. Surgery was performed under a surgical micro-
scope. Through a midline neck incision, a tracheostomy
was performed, and mechanical ventilation started with
room air (Minivent 845; Hugo Sachs/Harvard Apparatus,
March-Hugstetten, Germany). Subsequently, a 1.4Fr high-
ﬁdelitypressure-conductancecatheter(1.4-Fr,SPR-839;Mil-
lar Instruments, Houston, TX) was inserted through the
right carotid artery into the left ventricle, and left ven-
tricular pressure-conductance measurements were started.
After stabilization of the hemodynamic situation, baseline
pressure-volume (PV) loops were recorded (PowerLab/4SP
ADInstruments, Castle Hill, Australia), while the ventilation
was momentarily turned oﬀ to avoid respiratory ﬂuctuation
of cardiac signals. The inferior caval vein was compressed
between liver and diaphragm with a cotton swab without
opening the abdomen, while PV loops were recorded to
obtain occlusion loops with progressively lowering preload.
Afterwards a 24G catheter was introduced in the right
jugular vein, and parallel volume was determined by a bolus
injection of 3μL of 30% sodium chloride solution while
recording PV loops. Following baseline measurements, an
intravenous line was prepared with isoproterenol, and dose
was increased gradually from 3, 9, 30 to ﬁnally 90ng/kg/min.
Dose-response curves of the load-dependent and load-
independent contractility parameters to isoproterenol infu-
sion were obtained ﬁnally. A laparotomy was performed, and
the inferior caval vein was exposed infrahepatically. With a
24G needle, 300μL of blood was retrieved from the inferior
c a v a lv e i nt om e a s u r es p e c i ﬁ cc o n d u c t i v i t yi n3p r e c a l i b r a t e d
cuvettes.
2.4. Data Management and Statistical Analysis. Analysis after
IPGTTtestingincludedcalculationofpeakglucoselevelsand
area under the curve. Peak glucose levels were obtained 30
minutes after bolus injection and expressed as mg/dL. Areas
under the curve were calculated as the sum of the measured
values, normalized for the time interval, and expressed in
mg·h/dL.
Analysis of the pressure-conductance data was per-
formed using PVAN 3.2 software (Millar Instruments,
Houston, TX). A conductance-volume calibration line was
constructed with the cuvette data. All data were corrected
for parallel volume and expressed in absolute volumes. Only
technically acceptable loops were included in the analysis for
each experiment [30].
Data are expressed as mean ± standard deviation.
Signiﬁcant changes were detected by single regression, and
normality was assessed by the Shapiro-Wilk W test. Baseline
diﬀerences between groups were compared by breakdown
one-way ANOVA, followed by an LSD post hoc test and a
repeated measurements ANOVA when data was normally
distributed. The nonparametric Mann-Whitney U test and
Wilcoxon Matched Pairs test was used when data was not
normally distributed, and the Kruskal-Wallis ANOVA was
used to compare survival between strains. Statistical software
(Statistica 8, StatSoft) was used. A value of P<. 05 was
considered signiﬁcant.Journal of Biomedicine and Biotechnology 3
Table 1: Morphology in 4 mice background strains. All data are expressed as mean ± standard deviation. Values marked with ∗ are P<. 05
versus all others.
Swiss C57BL6/J DBA2 BalbC
Body weight (BW) (g) 44.8 ± 5.1∗ 26.1 ± 4.6 27.1 ± 2.7 27.0 ± 2.8
H e a r tw e i g h t( g ) 0 . 1 9± 0.03∗ 0.14 ± 0.02 0.14 ± 0.02 0.14 ± 0.01
Tibial length (um) 193 ± 7∗ 185 ± 7 175 ± 3 174 ± 4
HW/TL (g/100um) 99.36 ± 16.08∗ 77.62 ± 10.99 82.94 ± 14.21 79.64 ± 8.66
HW/BW (mg/g) 4.26 ± 0.41∗ 5.51 ± 0.31 5.31 ± 0.48 5.13 ± 0.31
0
100
200
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Time after injection of bolus glucose 20% (min)
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Figure 1: Intraperitoneal glucose tolerance testing in 4 background
strains at 23 weeks. Lean values are similar between the studied
groups. Values after 15, 30, and 60 minutes are signiﬁcantly higher
in C57BL/6J mice versus other strains. Values with P<. 01 are
marked with∗.
3. Results
3.1. Mortality and Morphology. Between 12 and 24 weeks of
age, 1 BalbC, 1 DBA2, and 2 Swiss mice died a sudden unex-
plained death. During the experimental procedure, 1 Swiss
mouse and 2 BalbC mice died during the baseline pressure-
conductance measurements. Under increasing isoproterenol
dose, in total, 4 Swiss, 6 C57BL/6J, 2 DBA2, and 7 BalbC
mice died before 90ng/kg/min isoproterenol was reached.
Survival during the experimental protocol was signiﬁcantly
lower in BalbC mice versus the other strains and occurred
mainly during isoproterenol infusion (P<. 05).
Heart weight (HW), body weight (BW), tibial length
(TL), and HW/TL were signiﬁcantly higher in Swiss mice at
2 4w e e k sv e r s u sa l lo t h e rs t r a i n s( P<. 01 for HW and BW,
P<. 05 for TL and HW/TL). Heart weight over body weight
(HW/BW) was signiﬁcantly lower in Swiss mice (P<. 001,
versus all); see Table 1.
3.2. IPGTT Testing. Fasting glucose levels at 24 weeks
were comparable between the four studied strains. During
intraperitoneal glucose tolerance testing, all mice showed
as t r o n gi n c r e a s ei nb l o o dg l u c o s ev a l u e s( Figure 1). In
C57BL/6Jmice,thepeakglucoselevelafter30minutes(418±
65) was signiﬁcantly higher than the Swiss (237 ± 66mg/dL,
P<. 001), the DBA2 (113 ± 20mg/dL, P<. 001), and the
BalbC group (174 ± 55mg/dL, P<. 001). AUC in C57BL/6J
micewas813±100mg·h/dL,andthiswassigniﬁcantlyhigher
than in the Swiss (470 ± 126mg·h/dL, P<. 01), the DBA2
(304 ± 49mg·h/dL, P<. 01), and the BalbC group (416 ±
70mg·h/dL, P<. 001).
3.3. Baseline Cardiac Performance (Table 2). At baseline,
Swiss mice had the fastest heart rate (P<. 01 versus all other
strains). End-systolic pressure (Pes) was higher in BalbC mice
versus the Swiss, DBA2, and C57BL/6J mice (P<. 05 for all).
End-systolic volume (Ves) was lower in Swiss and DBA2 mice
versus C57BL/6J and BalbC mice (both P<. 01), while end-
diastolic volume (Ved) was only signiﬁcantly lower in DBA2
versus C57BL/6J (P<. 05). The maximal systolic pressure
(Pmax) was higher in Swiss versus C57BL/6J (P<. 05) but not
versus DBA2 or BalbC. Ejection fraction (EF) was higher in
DBA2 and Swiss mice versus C57BL/6J mice and BalbC mice
(both P<. 001), and stroke volume (SV) was higher in Swiss
versus C57BL/6J and BalbC mice (P<. 05) but not versus
DBA2 mice (P = .22).
Cardiac output (CO) and maximal rate of pressure
development during isovolumetric contraction (dPdtmax)
were higher in Swiss versus C57BL/6J (P<. 01 and P<. 001),
DBA2 (P<. 01 and P<0.05), and BalbC mice (both
P<. 001). Tau was higher in BalbC and C57BL/6J mice
versusSwissandDBA2mice(bothP<. 05),butthe maximal
rate of pressure decay (dPdtmin) was comparable between
the studied strains. Arterial elastance (Ea) was signiﬁcantly
higher in BalbC mice versus other strains (all P<. 05).
The load-independent p r e l o a dr e c r u i t a b l es t r o k ew o r k
(PRSW) and the end-systolic elastance (Ees) were not signif-
icantly diﬀerent between the four studied groups (P>. 05).
The slope of the end-diastolic pressure-volume relationship
(slope EDPVR) was higher in BalbC mice (P<. 05), but
the parameter of mechanical eﬃciency of the left ventricle
( s t r o k ew o r kt oP Va r e a( P V A )r a t i o ,SW/PVA) was lower in
BalbC mice versus the other groups (P<. 05).
3.4. Changes in Cardiac Performance under Increasing Iso-
proterenol Infusion (See Table 3 and Figure 2). All species4 Journal of Biomedicine and Biotechnology
Table 2: Pressure-conductance analysis in 4 mice background strains. All data are expressed as mean ± standard deviation. Values marked
with ψ are P<. 05 versus  and values marked with ∗ are P<. 05 versus all others.
Heart rate (bpm) 623 ± 71∗ 569 ± 43 545 ± 40 566 ± 35
Ves (uL) 10.9 ± 5.1ψ 16.5 ± 6.2 9.0 ± 3.1ψ 18.0 ± 4.6
Ved (uL) 30.7 ± 9.1 31.8 ± 7.2ψ 25.8 ± 7.1 30.0 ± 9.9
Pes (mmHg) 69.5 ± 9.9 76.8 ± 8.2 71.9 ± 8.0 84.2 ± 13.6∗
Ped (mmHg) 1.2 ± 1.7 1.9 ± 2.0 1.2 ± 1.2 2.9 ± 2.9
Pmax (mmHg) 90 ± 5ψ 84 ± 6 88 ± 78 9 ± 11
EF (%) 70.4 ± 11.2 55.9 ± 13.4ψ 71.8 ± 9.2 47.8 ± 5.7ψ
Cardiac output (uL/min) 14038 ± 4530∗ 10405 ± 2683 10438 ± 3251 8466 ± 3013
dP/dtmax (mmHg/s) 11746 ± 2105∗ 7162 ± 1563 9420 ± 2268 7760 ± 1581
dP/dtmin (mmHg/s) −7738 ± 2098 −7948 ± 1242 −8204 ± 1458 −8547 ± 1464
Tau 4.1 ± 0.7ψ 5.2 ± 0.9 4.5 ± 0.7ψ 5.2 ± 0.8
Arterial elastance (Ea) (mmHg/μL) 3.4 ± 1.2 4.4 ± 1.2 4.1 ± 1.1 6.2 ± 1.9∗
Ees 9.5 ± 5.0 6.1 ± 2.1 8.4 ± 3.8 8.2 ± 2.9
EDPVR (mmHg/μL) 0.265 ± 0.082 0.218 ± 0.074 0.316 ± 0.079 0.415 ± 0.159∗
Preload recruitable stroke work (PRSW) (mmHg) 92 ± 22 88 ± 21 94 ± 25 82 ± 23
Eﬃciency (SW/PVA) 0.78 ± 0.054 0.70 ± 0.08 0.70 ± 0.13 0.60 ± 0.11∗
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Figure 2: Illustration of the increase in heart rate under isopro-
terenol infusion in the four studied mice background strains.
showed an increase in HR during isoproterenol infusion
(Figure 2), but the HR increase was signiﬁcantly larger in
BalbCversusSwissmice(P<. 05)(meanincreaseof34±12%
inBalbCmiceversus19±12%inSwiss,23±9%inC57BL/6J,
and 25 ±11% in DBA2 mice).
Under isoproterenol, Pes, Ped, and Ved decreased in all
strains (P<. 05). Ejection fraction increased in C57BL/6J,
DBA2, and BalbC mice (P<. 0 5 )a n dt e n d e dt oi n c r e a s ei n
Swiss mice (P = .06). All species show a progressive decrease
in tau under increasing isoproterenol dose (all P<. 05).
End-systolic elastance (Ees) increased signiﬁcantly under
isoproterenol in DBA2 and BalbC mice between 0 and
90ng/kg/min (P<. 05). There were no signiﬁcant changes
in Ees in the Swiss or C57BL/6J group. However, the increase
in PRSW only reached statistical signiﬁcance in the BalbC
group and not in the DBA2 mice.
4. Discussion
This study shows that left ventricular contractility and
glucose handling capacity are signiﬁcantly diﬀerent in four
mice background strains frequently used in cardiovascular
research. Overall survival under isoproterenol infusion with
invasive left ventricular contractility measurements was
diﬀerent between the studied strains.
4.1. Heart Weight. Body weight, heart weight, and left
ventricular weight are signiﬁcantly higher in Swiss versus the
other studied strains. Although Swiss mice are at 24 weeks
heavier than the other background strains, tibial length
did not show an increase to the same extent as the heart
weight increase, and this results in a higher HW/TL. In
contrast, HW/BW was lower in Swiss mice, because BW
increase was more pronounced than the HW increase. HW
over body surface area did not show signiﬁcant diﬀerences
between the 4 groups. When LV hypertrophy is studied,
it is probably more safe to report HW/TL, HW/BW, and
HW/BSA simultaneously.
4.2. IPGTT Testing. IPGTT in C57BL67/J showed higher
peak glucose levels and a higher AUC versus the other
strains. This suggests that capacity for glucose handling at
24 weeks is lower in C57BL/6J, although fasting glucose
levels are not increased. These ﬁndings are in accordance
with the ﬁndings of Gerich [9] and Vardeny et al. [12],
and it is therefore beneﬁcial to perform IPGTT testing,
especially when transgenic models against a C57BL/6J mice
background are studied.Journal of Biomedicine and Biotechnology 5
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4.3. Baseline Cardiac Performance. Swiss mice exhibited a
higher heart rate than the other strains, despite their higher
body weight. An increased cardiac output to meet the
metabolic demands of a larger individual is thus obtained by
a combination of a higher resting HR and a relatively high
SV.
Arterial elastance (Ea), a parameter for afterload, was
higher in BalbC mice. Afterload is inﬂuenced by peripheral
vascular resistance, arterial compliance, aortic characteristic
impedance, and systolic and diastolic time intervals, and
therefore any increase in afterload results in a decreased
stroke volume, unless contractility is increased. The higher
Ea can partially be explained by the higher systolic blood
pressures described in BalbC mice (Schlager and sides [1]),
and this is in accordance with the higher Pes that we found
inbothBalbCandespeciallyC57BL/6JmiceversusSwissand
DBA2 mice.
dP/dtmax is dependent on preload, Ved, and Ped. Diﬀer-
ences in dP/dtmax are useful to assess directional changes in
inotropic state, but changes in preload are to be evaluated
simultaneously. We found a signiﬁcantly higher dP/dtmax
in the Swiss mice, but, because heart rate was also higher
in Swiss mice, load-independent contractility parameters
should be assessed in order to compare LV contractility
safely. PRSW was not diﬀerent between the 4 studied strains.
The relatively high slope EDPVR in BalbC mice together
with the higher Tau suggest a reduced compliance of the
ventricular wall in BalbC mice. Epicardial mineralisation
or cardiac calcinosis, that are frequently found in this
strain [22, 23], could contribute to these functional changes.
SW/PVA was lowest in the BalbC group, indicating that their
contractile eﬃciency is relatively low.
4.4. Changes under Isoproterenol. Isoproterenol aﬀects the β2
receptors of skeletal muscle arterioles, inducing vasodilata-
tion, and interacts with the cardiac β1 receptors, potentially
leading to a positive inotropic and chronotropic eﬀect. We
observed a decrease in both Ped and Pes in all strains
and a strong chronotropic increase under isoproterenol
administration. The increase in HR was greater in BalbC
mice than in Swiss mice, and the decrease in slope EDPVR
was more pronounced in BalbC mice versus C57BL/6 mice.
Eesincreasedin both theDBA2andtheBalbCgroupbutwas
accompanied by a remarkable change of the PV loop shape
with asymmetric and highly peaking pressure-volume loops.
PRSW, a more robust parameter of LV contractility [31], did
only increase in the BalbC group.
These ﬁndings suggest that the cardiac β1 eﬀect in
these mice strains leads mainly to a chronotropic increase,
although isoproterenol infusion in BalbC mice results in an
increase in external work and eﬃciency for an increased
preload, as shown by the increasing PRSW in the higher
doses.
Glucose handling capacity was clearly reduced in
C57BL/6J mice at 24 weeks. Although cardiac performance
parameters were signiﬁcantly diﬀerent between the four
studied strains, C57BL/6J mice did not show a diﬀerence
in cardiac performance. Thus, the contractility changes that
have been reported for experimental mice models of diabetes
mellitus type 2 do not seem to precede the diabetic state.
Most likely, pronounced and sustained hyperglycemia is
required to clearly inﬂuence cardiac performance parame-
ters.
5. Conclusion
Swiss mice were signiﬁcantly larger at 24 weeks with incon-
sistent cardiac hypertrophy parameters. Glucose handling
capacity was reduced in C57BL/6J mice, but this did not lead
to a pronounced diﬀerence in cardiac performance. Survival
under increasing isoproterenol dose was signiﬁcantly lower
in the BalbC mice. Although baseline cardiac performance
was diﬀerent between the 4 studied strains, the load-
independent PRSW was comparable.
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